Prosight Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Prosight Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,382	Closed	-$4.1M	–	39
2018 Q3	$4.1M	Sell	11,382 -3,232	-22%	-$1.11M	2.28%	20
2018 Q2	$5.35M	Sell	14,614 -3,081	-17%	-$1.1M	3.92%	12
2018 Q1	$5.23M	Sell	17,695 -4,931	-22%	-$1.46M	3.28%	11
2017 Q4	$9.47M	Buy	+22,626	New	+$8.08M	6.96%	4

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management's EIGR Position: Q4 2018 in Review

Prosight Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2018, closing a stake of 11,382 shares — an estimated $4.1M sold.

Prosight Management first reported a position in EIGR in Q4 2017 and held it in 4 quarters. The position peaked at $9.47M in Q4 2017. 68 funds tracked by Wall St. Rank hold EIGR as of Q4 2018.

Prosight Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Prosight Management sold 11,382 Eiger BioPharmaceuticals, Inc. shares in Q4 2018, an estimated $4.1M.
Prosight Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Prosight Management's Eiger BioPharmaceuticals, Inc. position peaked at $9.47M in Q4 2017.
68 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2018.

Based on Prosight Management's 13F filing for Q4 2018, filed 14 Feb 2019.